Unicycive Therapeutics (UNCY)

• Market cap: $129M
• 1 day: -7.26%
• 5 days: 10.5%
• 1 month: 35.14%
• 3 months: 38.89%
• 6 months: -9.37%
• Year to date: -24.24%
• 1 year: -18.48%
• 5 years: -89.74%
• 10 years: -89.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22